One of the obstacles of immune cell therapy is the presence of an immunosuppressive tumor microenvironment.23 PD-1/PD-L1 inhibitory signal is the thoroughly studied immunosuppressive pathway, and antibodies targeting PD-1/PD-L1 have gained approval for treating various types of tumors. This evidence concerns the gene CD274 and neoplasm.